|
|
|
|
|
|||||||
|
Session 24
Oral Abstract Session
Antiretroviral Chemotherapy: Pathogenesis of Primary HIV Infection Wednesday, 10 am - 12:30 pm 6A-B |
| Moderators | William Duncan, NIAID, NIH, Bethesda, MD and Joep Lange, NATEC, Academic Med. Ctr., Amsterdam,
The Netherlands | ||
| 10:00 91. | The Presence of HLA-B*5701, -DRB1*0701, and -DQ3 Is Highly Predictive of Hypersensitivity to the HIV Reverse Transcriptase Inhibitor Abacavir S. Mallal*1, D. Nolan1, C. Witt2, G. Masel1, 2, A. Martin1, C. Moore1, D. Sayer1, 2, A. Castley2, C. Mamotte1, 2, D. Maxwell1, I. James1, and F. Christiansen2 1Ctr. for Clin. Immunology and Biomed. Statistics, Royal Perth Hosp., Australia and 2Univ. of Western Australia, Murdoch, Perth, Australia
| ||
| 10:15 92. | HLA-B57 and TNF- S. Hetherington*, A. Hughes, M. Mosteller, D. Shortino, K. Baker, E. Lai, M. Stocum, and A. Roses GlaxoSmithKline, Res. Triangle Park, NC
| ||
| 10:30 93. | Are Episodes of Transient Viremia ("Blips" in HIV RNA) Predictive of Virologic Failure in Heavily Treatment-Experienced Patients? D. Havlir*1, R. Bassett2, V. DeGruttola2, S. Hammer3, R. Gulick4, and J. Mellors5 for the ACTG 359 and 398 Teams 1Univ. of California, San Diego; 2Harvard Sch. of Publ. Hlth., Boston, MA; 3Columbia Univ, New York, NY; 4Cornell Univ, New York, NY; and 5Univ. of Pittsburgh, PA
| ||
| 10:45 94. | Viral Blip Dynamics during HAART M. Di Mascio*1, M. Markowitz2, M. Louie2, A. Hurley2, D. Ho2, and A. S. Perelson1 1Los Alamos Natl. Lab., NM and 2Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY
| ||
| 11:00 95. | Persistence of Transmitted Drug Resistance among Subjects with Primary HIV Infection not Receiving Antiretroviral Therapy S. J. Little*1, E. S. Daar2, S. Holte3, S. D. W. Frost1, J. P. Routy4, M. Markowitz5, A. C. Collier6, J. Margolick7, R. Koup8, B. Conway9, E. Connick10, M. Kilby11, T. Wrin12, C. J. Petropoulos12, N. S. Hellmann12, and D. D. Richman13 1Univ. California, San Diego; 2Cedars-Sinai Med. Ctr., Los Angeles, CA; 3Fred Hutchinson Cancer Res. Ctr., Seattle, WA; 4McGill Univ. Hlth. Ctr., Montreal, Quebec, Canada; 5Aaron Diamond AIDS Res. Ctr., Rockefeller Univ., New York, NY; 6Univ. of Washington, Seattle; 7Johns Hopkins Univ. Sch. of Publ. Hlth., Baltimore, MD; 8NIAID, NIH Vaccine Res. Ctr., Bethesda, MD; 9Univ. of British Columbia, Vancouver, Canada; 10Univ. of Alabama, Birmingham; 11Univ. of Colorado, Denver; 12ViroLogic, Inc., South San Francisco, CA; and 13VA Med. Ctr., San Diego, CA
| ||
| 11:15 96. | Mixed Infection with Multidrug Resistant (MDR) and Wild Type HIV Strains in Primary HIV Infection (PHI): Early Viral Rebound Suggests Loss of Immune Control E. S. Daar*1, S. D. W. Frost2, J. K. Wong2, N. S. Hellmann3, T. Wrin3, C. J. Petropoulos3, D. D. Richman2, J. A. Pitt1, S. J. Little2, and A. J. Leigh Brown2 1Cedars-Sinai Med. Ctr., Univ. of California, Los Angeles; 2Univ. of California, San Diego; 3ViroLogic, Inc., South San Francisco, CA; and 4Univ. of Edinburgh, UK
| ||
| 11:30 97. | Initiation of Treatment before Seroconversion Increases the Rate of Clearance of the Latent Reservoir M. C. Strain*1, S. J. Little1, E. S. Daar2, H. Gunthard3, C. Spina1,4, R. Y. Lam1, O. A. Daly4, C. Ignacio1, T. Macaranas1, S. Kwok5, C. Christopherson5, J. Santangelo1, J. Pitt4, D. D. Richman1,4, J. K. Wong1, and 1Univ. of California San Diego; 2Cedars-Sinai Med. Ctr., Los Angeles, CA; 3Univ. Hosp., Zurich, Switzerland; 4VA San Diego Healthcare System, CA; and 5Roche Molecular Systems, Alameda, CA
| ||
| 11:45 98. | Acute Phase CTL Escape Is a Hallmark of Simian Immunodeficiency Virus Infection D. H. O’Connor*1, T. M. Allen1, T. U. Vogel1, P. Jing1, I. P. DeSouza1, E. Dodds1, E. J. Dunphy1, C. Melsaether1, B. Mothé1, H. Horton1, A. L. Hughes2, and D. I. Watkins1 1Wisconsin Regional Primate Res. Ctr., Madison and 2Univ. of South Carolina, Columbia
| ||
| 12:00 99. | Accumulation of DC-SIGN+ CD40+ Dendritic Cells with Reduced CD80 and CD86 Expression in Lymphoid Tissue during Acute HIV-1 Infection K. Lore*1,2, A. Sonnerborg2, C. Brostrom2, L. Goh3, L. Perrin4, H. McDade3, H. J. Stellbrink5, B. Gazzard6, R. Weber7, L. A. Napolitano8, Y. van Kooyk9, and J. Andersson2 1 NIAID Vaccine Res. Ctr., NIH, Bethesda, MD; 2Karolinska Inst., Huddinge Univ. Hosp., Stockholm, Sweden; 3GlaxoSmithKline, Middlesex, UK; 4Geneva Univ. Hosp., Switzerland; 5Universitatsklinikum Eppendorf, Hamburg, Germany; 6Chelsea & Westminster Hosp., London, UK; 7Royal Free Hosp., London, UK; 8Univ. of San Francisco, CA; and 9Free Univ. Med. Ctr., Amsterdam, The Netherlands
| ||
| 12:15 100. | Correlates of Viral Diversity in Primary HIV-1 Infection in Women M. Sagar*1,2, L. Lavreys3, J. Baeten2, B. Richardson2, K. Mandaliya3, J. Kreiss2, and J. Overbaugh1 1Fred Hutchinson Cancer Res. Ctr., Seattle; 2Univ. of Washington, Seattle; and 3Coast Provincial Gen. Hosp., Mombasa, Kenya
|
